Repertoire Immune Medicines signed a collaboration with Eli Lilly to develop tolerizing therapies for multiple autoimmune diseases. Financial terms include an $85 million upfront payment and up to roughly $1.84–1.92 billion in milestones plus royalties. Repertoire’s Decode platform, which maps T‑ and B‑cell repertoires to identify tolerogenic targets, will support discovery and candidate selection. Repertoire’s CEO Torben Straight Nissen called the deal the company’s largest, adding that the Lilly partnership validates the proprietary platform after similar collaborations with Bristol Myers Squibb and Genentech. The agreement accelerates Repertoire’s clinical translation timeline by leveraging Lilly’s development and commercialization infrastructure. For the autoimmune field, the transaction signals pharma confidence in repertoire‑driven tolerizing approaches and increases competition and investment in antigen‑specific immune modulation.